KLAR Stock Overview
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.30 |
| 52 Week High | kr0.78 |
| 52 Week Low | kr0.14 |
| Beta | 0.30 |
| 1 Month Change | 20.00% |
| 3 Month Change | -41.18% |
| 1 Year Change | -51.61% |
| 3 Year Change | -97.00% |
| 5 Year Change | -96.96% |
| Change since IPO | -94.00% |
Recent News & Updates
Shareholder Returns
| KLAR | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -20.0% | 3.3% | 1.7% |
| 1Y | -51.6% | 54.7% | 14.7% |
Return vs Industry: KLAR underperformed the Swedish Pharmaceuticals industry which returned 49.6% over the past year.
Return vs Market: KLAR underperformed the Swedish Market which returned 14.1% over the past year.
Price Volatility
| KLAR volatility | |
|---|---|
| KLAR Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.9% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: KLAR's share price has been volatile over the past 3 months.
Volatility Over Time: KLAR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 5 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
| KLAR fundamental statistics | |
|---|---|
| Market cap | kr31.95m |
| Earnings (TTM) | -kr35.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs KLAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLAR income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr35.78m |
| Earnings | -kr35.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KLAR perform over the long term?
See historical performance and comparison